Suppr超能文献

聚丙烯腈膜合成与释放血小板活化因子(PAF)的机制及动力学

Mechanisms and kinetics of the synthesis and release of platelet-activating factor (PAF) by polyacrylonitrile membranes.

作者信息

Guastoni C, Tetta C, Hoenich N A, Gervasio R, Sereni L, Tessore E, Wratten M L, Civati G

机构信息

Department of Nephrology and Dialysis Niguarda-Ca' Granda Hospital, Milan, Italy.

出版信息

Clin Nephrol. 1996 Aug;46(2):132-8.

PMID:8869791
Abstract

Platelet-activating factor is a recognized mediator of anaphylaxis and bioincompatibility. Here, the mechanisms and the kinetics of the production of platelet-activating factor were studied in vivo during high-flux hemodialysis and in vitro in a recirculation model with polyacrylonitrile membranes, the AN-69 and the more recent SPAN, where the Na-metallilsulfonate group is partially substituted with the less polar methacrylate group. In in vivo studies, eleven patients were studied in cross over. Patients were randomly allocated to the AN-69 (5 patients) and to the SPAN membrane (6 patients) for two weeks. Measurements were made in the second week of use. After completion of the second week, the patients were switched to the other membrane for a further two weeks. Samples for leukocyte and platelet counts, PAF in whole blood or bound to platelets, the C3a des Arg and the C5b-C9 membrane attack complex as well as samples for clearances of urea, creatinine and phosphates were taken at different time intervals during treatment. PAF was detected by biological assay after methanol extraction of whole blood or of platelet pellets obtained by sequential centrifugation. C3a des Arg and the C5b-C9 fraction were detected by commercially available immunoassays. Results were analyzed by Minitab statistical package. PAF was detectable only during treatment with AN-69 but not with SPAN 1 min after start of the extracorporeal circulation in both whole blood (4.5 +/- 2.7 ng/ml) and on platelet surface (4.1 +/- 1.2 ng/ml). No statistical significant differences were observed between AN-69 and SPAN with regard to leukocyte and platelet counts, plasma C3a des Arg and C5b-C9 levels. The structure modification did not alter functional performances as indicated by the lack of statistically significant differences in clearance values between the two membranes. In in vitro experiments performed with normal washed and whole blood recirculated in a closed circuit demonstrated the presence of a plasma-dependent, complement-independent mechanisms responsible for the triggering of PAF synthesis and release with AN-69 but not SPAN membrane. PAF was extractable from the inner and outer side of both polyacrylonitrile membranes (AN-69: inner, 4.9 +/- 0.5 ng/ml; outer, 0.1 +/- 0.05 ng/ml; SPAN: inner, 5.5 +/- 0.6 ng/ml, outer: 3.3 +/- 0.7 ng/ml, SPAN vs. p < 0.001), suggesting that absorption may be relevant with both membranes.

摘要

血小板活化因子是一种公认的过敏反应和生物不相容性介质。在此,我们研究了高通量血液透析过程中体内血小板活化因子的产生机制和动力学,以及在体外使用聚丙烯腈膜(AN - 69和更新的SPAN,其中磺酸钠基团部分被极性较小的甲基丙烯酸酯基团取代)的再循环模型中的情况。在体内研究中,对11名患者进行了交叉研究。患者被随机分配到AN - 69组(5名患者)和SPAN膜组(6名患者),为期两周。在使用的第二周进行测量。第二周结束后,患者更换为另一种膜,再进行两周。在治疗期间的不同时间间隔采集白细胞和血小板计数样本、全血或结合在血小板上的血小板活化因子样本、C3a去精氨酸片段和C5b - C9膜攻击复合物样本,以及尿素、肌酐和磷酸盐清除率样本。通过对全血或经连续离心获得的血小板沉淀进行甲醇提取后,采用生物测定法检测血小板活化因子。通过市售免疫测定法检测C3a去精氨酸片段和C5b - C9组分。结果采用Minitab统计软件包进行分析。在体外循环开始1分钟后,仅在使用AN - 69治疗期间全血(4.5±2.7 ng/ml)和血小板表面(4.1±1.2 ng/ml)可检测到血小板活化因子,而使用SPAN时未检测到。在白细胞和血小板计数、血浆C3a去精氨酸片段和C5b - C9水平方面,AN - 69和SPAN之间未观察到统计学上的显著差异。如两种膜之间清除率值缺乏统计学显著差异所示,结构修饰并未改变功能性能。在体外实验中,用正常洗涤的全血在封闭回路中再循环,结果表明存在一种血浆依赖性、补体非依赖性机制,该机制负责在使用AN - 69膜时触发血小板活化因子的合成和释放,而使用SPAN膜时则不会。血小板活化因子可从两种聚丙烯腈膜的内侧和外侧提取(AN - 69:内侧,4.9±0.5 ng/ml;外侧,0.1±0.05 ng/ml;SPAN:内侧,5.5±0.6 ng/ml,外侧:3.3±0.7 ng/ml,SPAN与AN - 69相比,p < 0.001),这表明吸附可能与两种膜都有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验